KRAS and cancer: KRAS mutation detected by cfDNA was a significant prognostic biomarker in cancer patients either in Asian (HR 1.81, 95% CI 1.29–2.53, P<0.01) or others population (HR 2.21, 95% CI 1.63–2.51, P<0.01) (Fig 5).